WHAT IS CLAIMED IS :

1. 7-(3-Aminomethyl-4-methoxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate.

2. 7-(3-Aminomethyl-4-methoxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate.nH_2O, wherein n is in the range of from 1 to 4.

3. A compound according to claim 2 wherein n is 1.5.

4. A compound according to claim 2 having peaks at 2θ = 8.0, 12.2 and 14.7° in its X-ray diffraction pattern.

5. A compound according to claim 2 having an X-ray diffraction pattern substantially as shown in Figure 7.

6. A compound according to claim 2 wherein n is 3.

7. A compound according to claim 2 having peaks at 2θ = 7.7 and 11.8° in its X-ray diffraction pattern.

8. A compound according to claim 2 having an X-ray diffraction pattern substantially as shown in Figure 6.

9. A compound according to claim 2 which has a moisture content of from 4 to 6%.

10. A compound according to claim 2 which has a moisture content

of from 9 to 11%.

11. A pharmaceutical composition comprising a compound according to any one of the preceding claims, together with a pharmaceutically acceptable carrier or excipient.

12. A compound according to any one of claims 1 to 10, for use as a pharmaceutical.

13. A method of treating bacterial infections in humans and animals which comprises administering a therapeutically effective amount of a compound according to any one of claims 1 to 10.

14. The use of a compound according to any one of claims 1 to 10 for the manufacture of a medicament for treating bacterial infection.

15. A process for the preparation of a compound according to any one of claims 1 to 10, which comprises reacting 7-(3-aminomethyl-4-methoxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid with methanesulfonic acid and crystallizing the resulting compound from solution, and where desired or necessary, adjusting the hydration of the compound.

16. A process for the preparation of a compound according to any one of claims 2 to 10, comprising exposing 7-(3-aminomethyl-4-methoxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate anhydrate or a solvate thereof to a relative humidity of at least 75%.

17. A process according to claim 16, wherein the solvate is a solvate

with one or more organic solvents selected from C_1-C_4 haloalkanes and C_1-C_8 alcohols.

18. A solvate of 7-(3-aminomethyl-4-methoxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate with one or more organic solvents.